コンパニオンアニマル用医薬品の世界市場 (2019-2029年)：動物・投与経路・製品・地域別の市場規模・シェア・動向分析・機会・予測

世界のコンパニオンアニマル用医薬品の市場規模は、2022年の348億米ドルから、予測期間中は4.42％のCAGRで推移し、2029年には451億2,000万米ドルの規模に成長すると予測されています。

市場の主な成長促進要因としては、ペットの飼育数の増加、ペットの病気の有病率の上昇、ペットの健康の重要性に対する認識の高まりなどが挙げられます。また、動物の健康に対する支出の増加に伴うペット保険需要の急増、動物ヘルスケアに関するR&D投資の増加、世界のペット飼育率の高さなどがも予測期間中の市場をさらに牽引すると期待されています。

当レポートでは、世界のコンパニオンアニマル用医薬品の市場を調査し、市場概要、市場成長への各種影響因子の分析、技術動向、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界のコンパニオンアニマル用医薬品市場に関する洞察

• 産業のバリューチェーン分析
• DROC分析
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• 製品の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析

第4章 世界のコンパニオンアニマル用医薬品市場：概要

• 市場規模・予測
• 市場シェア・予測
  • 動物別
    • 犬
    • 猫
    • 馬
    • その他
  • 投与経路別
    • 経口
    • 注射
    • 局所
  • 製品別
    • 抗生物質
    • 抗炎症薬
    • 寄生虫駆除剤
    • ワクチン
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ

第5章 北米のコンパニオンアニマル用医薬品市場

• 市場規模・予測
• 市場シェア・予測
  • 動物別
  • 投与経路別
  • 製品別
  • 国別

第6章 欧州のコンパニオンアニマル用医薬品市場

• 市場規模・予測
• 市場シェア・予測
  • 動物別
  • 投与経路別
  • 製品別
  • 国別

第7章 アジア太平洋のコンパニオンアニマル用医薬品市場

• 市場規模・予測
• 市場シェア・予測
  • 動物別
  • 投与経路別
  • 製品別
  • 国別

第8章 ラテンアメリカのコンパニオンアニマル用医薬品市場

• 市場規模・予測
• 市場シェア・予測
  • 動物別
  • 投与経路別
  • 製品別
  • 国別

第9章 中東・アフリカのコンパニオンアニマル用医薬品市場

• 市場規模・予測
• 市場シェア・予測
  • 動物別
  • 投与経路別
  • 製品別
  • 国別

第10章 競合情勢

• 主要企業・製品リスト
• 市場シェア分析
• 競合ベンチマーキング：経営パラメーター別
• 主要な戦略的展開 (M&A・提携など)

第11章 世界のコンパニオンアニマル用医薬品市場に対するCOVID-19の影響

第12章 企業プロファイル (企業概要・財務マトリックス・競合情勢・主要人材・主な競合相手・連絡先・戦略的展望・SWOT分析)

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• Bayer AG
• Virbac
• Dechra Pharmaceuticals PLC
• Vetoquinol SA
• Ceva Sante Animale
• Kindred Biosciences, Inc.
• Norbrook
• IDEXX Laboratories, Inc.
• Animalcare Group plc
• Neogen Corporation
• Heska Corporation
• その他の主要企業

第13章 主な戦略的提言

第14章 調査手法

Global Companion Animal Pharmaceuticals Market Size Set to Touch USD 45.12 Billion by 2029.

Global companion animal pharmaceuticals market is flourishing because of an increasing awareness about animal health and wellness, rising pet ownership, increasing humanization of pets, and growing adoption of technology advancements in veterinary healthcare.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global companion animal pharmaceuticals market size at USD 34.8 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global companion animal pharmaceuticals market size to grow at a CAGR of 4.42% reaching a value of USD 45.12 billion by 2029. Major growth drivers for the global companion animal pharmaceuticals market include an increasing number of pet adoptions, the rising prevalence of pet diseases, and the growing awareness of the importance of pet health. Also, a surge in demand for pet insurance owing to the rising expenditure on animal health, escalating investments in R&D for animal healthcare, and high rates of pet ownership across the globe are expected to further drive the global market during the period in analysis. However, stringent regulations and lengthy approval processes for animal pharmaceuticals and high costs associated with veterinary drugs and treatments are anticipated to hinder the global market during the forecast period.

Global Companion Animal Pharmaceuticals Market - Overview:

A companion animal differs from an assistive animal in that it does not receive any specific training to help a person with a disability. Instead, companion animals provide humans with companionship, entertainment, emotional support, and other functions that humans need from animals. Veterinarians who specialize in companion animals can perform a range of medical services, including treating injuries and illnesses, performing surgeries, administering vaccines, and prescribing medications. They are also responsible for euthanizing animals when necessary. The owners of companion animals are responsible for the animal's well-being, actions, and care. When choosing a companion animal, it is essential to consider the owner's lifestyle, budget, and ability to provide proper care throughout the animal's life. Animal health products, such as feeds, are the most commonly used products for animal healthcare, and this market includes pharmaceuticals and vaccines that improve the health and welfare of animals. Animals obtain nutrition from these products. In recent years, the number of people who own and spend money on companion animals has increased, and pet owners now spend more money per pet than in the past. Pet owners prioritize their pet's health and wellness and expect them to live a healthy life.

Impact of COVID-19 on Global Companion Animal Pharmaceuticals Market

COVID-19 pandemic had a dual impact on the global companion animal pharmaceuticals market. On the positive side, with lockdowns and social distancing measures in place, people were spending more time at home and turning to pets for comfort and companionship. It led to an increase in pet ownership and a surge in demand for animal healthcare products and services, including pharmaceuticals. However, on the negative side, the pandemic disrupted global supply chains and manufacturing activities, causing shortages of raw materials and finished products. It led to production delays and increased prices, which affected the profitability of the market players. Moreover, with the focus on human healthcare during the pandemic, veterinary care and services were deprioritized in some regions, leading to a decline in demand for companion animal pharmaceuticals. Despite these challenges, the overall impact of the pandemic on the companion animal pharmaceuticals market was relatively moderate, and the market is expected to recover as the situation normalizes. As people continue to value the companionship of their pets, the demand for animal healthcare products and services is expected to remain robust in the long term.

Global Companion Animal Pharmaceuticals Market - By Animal

By animal, the global companion animal pharmaceuticals market is divided into Dogs, Cats, and Horses segments. The dogs segment held the highest share in the global companion animal pharmaceuticals market in 2022. According to Holland Insurance Company Pty. Ltd., India is experiencing an exponential growth in its pet dog population, driven by urbanization and millennials opting for dogs as pets. Also, the growing awareness of pet insurance and animal health importance is expected to boost the market growth. On the other hand, the cats' segment is projected to grow at the highest compound annual growth rate (CAGR) during the forecast period. Cats are becoming increasingly popular in certain countries like Canada and are preferred over dogs. Additionally, many companies are concentrating on expanding their product range for cats due to their greater susceptibility to diseases when compared to other pets.

Competitive Landscape:

Major players operating in the global companion animal pharmaceuticals market include: Nestle SA, The Hershey Company, Lindt & Sprungli AG, Mondelez International, Inc., Ferrero Group, Haribo GmbH & Co. KG, Perfetti Van Melle, Russell Stover Chocolates, Wrigley Jr. Company, Ricola AG, Chupa Chups SA, Jelly Belly Candy Company, Lotte Group, Swizzels Matlow Limited, and The Topps Company. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of the Global Companion Animal Pharmaceuticals Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Companion Animal Pharmaceuticals Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Companion Animal Pharmaceuticals Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Growing pet ownership and increasing humanization of pets
    • 3.2.1.2. Rising awareness about animal health and wellness
    • 3.2.1.3. Advancements in veterinary healthcare technology
  • 3.2.2. Restraints
    • 3.2.2.1. Stringent regulations and lengthy approval processes for animal pharmaceuticals
    • 3.2.2.2. High costs associated with veterinary drugs and treatments
  • 3.2.3. Opportunities
    • 3.2.3.1. Increasing demand for personalized and customized medicine for pets
    • 3.2.3.2. Rising trend of pet insurance, providing financial assistance for pet healthcare
  • 3.2.4. Challenges
    • 3.2.4.1. Concerns over the safety and efficacy of animal pharmaceuticals
    • 3.2.4.2. Lack of awareness and education about pet healthcare in certain regions
• 3.3. Product Advancements/Recent Developments
• 3.4. Regulatory Framework
• 3.5. Porter's Five Forces Analysis
  • 3.5.1. Bargaining Power of Suppliers
  • 3.5.2. Bargaining Power of Buyers
  • 3.5.3. Threat of New Entrants
  • 3.5.4. Threat of Substitutes
  • 3.5.5. Intensity of Rivalry

4. Global Companion Animal Pharmaceuticals Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Million)
• 4.2. Market Share and Forecast
  • 4.2.1. By Animal
    • 4.2.1.1. Dogs
    • 4.2.1.2. Cats
    • 4.2.1.3. Horses
    • 4.2.1.4. Others
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Oral
    • 4.2.2.2. Injectable
    • 4.2.2.3. Topical
  • 4.2.3. By Product
    • 4.2.3.1. Antibiotics
    • 4.2.3.2. Anti-inflammatory
    • 4.2.3.3. Parasiticides
    • 4.2.3.4. Vaccines
    • 4.2.3.5. Others
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia Pacific (APAC)
    • 4.2.4.4. Latin America (LATAM)
    • 4.2.4.5. Middle East and Africa (MEA)

5. North America Companion Animal Pharmaceuticals Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share & Forecast
  • 5.2.1. By Animal
  • 5.2.2. By Route of Administration
  • 5.2.3. By Product
  • 5.2.4. By Country
    • 5.2.4.1. United States
    • 5.2.4.1.1. By Animal
    • 5.2.4.1.2. By Route of Administration
    • 5.2.4.1.3. By Product
    • 5.2.4.2. Canada
    • 5.2.4.2.1. By Animal
    • 5.2.4.2.2. By Route of Administration
    • 5.2.4.2.3. By Product

6. Europe Companion Animal Pharmaceuticals Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Animal
  • 6.2.2. By Route of Administration
  • 6.2.3. By Product
  • 6.2.4. By Country
    • 6.2.4.1. Germany
    • 6.2.4.1.1. By Animal
    • 6.2.4.1.2. By Route of Administration
    • 6.2.4.1.3. By Product
    • 6.2.4.2. United Kingdom
    • 6.2.4.2.1. By Animal
    • 6.2.4.2.2. By Route of Administration
    • 6.2.4.2.3. By Product
    • 6.2.4.3. Italy
    • 6.2.4.3.1. By Animal
    • 6.2.4.3.2. By Route of Administration
    • 6.2.4.3.3. By Product
    • 6.2.4.4. France
    • 6.2.4.4.1. By Animal
    • 6.2.4.4.2. By Route of Administration
    • 6.2.4.4.3. By Product
    • 6.2.4.5. Spain
    • 6.2.4.5.1. By Animal
    • 6.2.4.5.2. By Route of Administration
    • 6.2.4.5.3. By Product
    • 6.2.4.6. Belgium
    • 6.2.4.6.1. By Animal
    • 6.2.4.6.2. By Route of Administration
    • 6.2.4.6.3. By Product
    • 6.2.4.7. Russia
    • 6.2.4.7.1. By Animal
    • 6.2.4.7.2. By Route of Administration
    • 6.2.4.7.3. By Product
    • 6.2.4.8. The Netherlands
    • 6.2.4.8.1. By Animal
    • 6.2.4.8.2. By Route of Administration
    • 6.2.4.8.3. By Product
    • 6.2.4.9. Rest of Europe
    • 6.2.4.9.1. By Animal
    • 6.2.4.9.2. By Route of Administration
    • 6.2.4.9.3. By Product

7. Asia-Pacific Companion Animal Pharmaceuticals Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Animal
  • 7.2.2. By Route of Administration
  • 7.2.3. By Product
  • 7.2.4. By Country
    • 7.2.4.1. China
    • 7.2.4.1.1. By Animal
    • 7.2.4.1.2. By Route of Administration
    • 7.2.4.1.3. By Product
    • 7.2.4.2. India
    • 7.2.4.2.1. By Animal
    • 7.2.4.2.2. By Route of Administration
    • 7.2.4.2.3. By Product
    • 7.2.4.3. Japan
    • 7.2.4.3.1. By Animal
    • 7.2.4.3.2. By Route of Administration
    • 7.2.4.3.3. By Product
    • 7.2.4.4. South Korea
    • 7.2.4.4.1. By Animal
    • 7.2.4.4.2. By Route of Administration
    • 7.2.4.4.3. By Product
    • 7.2.4.5. Australia & New Zealand
    • 7.2.4.5.1. By Animal
    • 7.2.4.5.2. By Route of Administration
    • 7.2.4.5.3. By Product
    • 7.2.4.6. Indonesia
    • 7.2.4.6.1. By Animal
    • 7.2.4.6.2. By Route of Administration
    • 7.2.4.6.3. By Product
    • 7.2.4.7. Malaysia
    • 7.2.4.7.1. By Animal
    • 7.2.4.7.2. By Route of Administration
    • 7.2.4.7.3. By Product
    • 7.2.4.8. Singapore
    • 7.2.4.8.1. By Animal
    • 7.2.4.8.2. By Route of Administration
    • 7.2.4.8.3. By Product
    • 7.2.4.9. Vietnam
    • 7.2.4.9.1. By Animal
    • 7.2.4.9.2. By Route of Administration
    • 7.2.4.9.3. By Product
    • 7.2.4.10. Rest of APAC
    • 7.2.4.10.1. By Animal
    • 7.2.4.10.2. By Route of Administration
    • 7.2.4.10.3. By Product

8. Latin America Companion Animal Pharmaceuticals Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Animal
  • 8.2.2. By Route of Administration
  • 8.2.3. By Product
  • 8.2.4. By Country
    • 8.2.4.1. Brazil
    • 8.2.4.1.1. By Animal
    • 8.2.4.1.2. By Route of Administration
    • 8.2.4.1.3. By Product
    • 8.2.4.2. Mexico
    • 8.2.4.2.1. By Animal
    • 8.2.4.2.2. By Route of Administration
    • 8.2.4.2.3. By Product
    • 8.2.4.3. Argentina
    • 8.2.4.3.1. By Animal
    • 8.2.4.3.2. By Route of Administration
    • 8.2.4.3.3. By Product
    • 8.2.4.4. Peru
    • 8.2.4.4.1. By Animal
    • 8.2.4.4.2. By Route of Administration
    • 8.2.4.4.3. By Product
    • 8.2.4.5. Rest of LATAM
    • 8.2.4.5.1. By Animal
    • 8.2.4.5.2. By Route of Administration
    • 8.2.4.5.3. By Product

9. Middle East & Africa Companion Animal Pharmaceuticals Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Animal
  • 9.2.2. By Route of Administration
  • 9.2.3. By Product
  • 9.2.4. By Country
    • 9.2.4.1. Saudi Arabia
    • 9.2.4.1.1. By Animal
    • 9.2.4.1.2. By Route of Administration
    • 9.2.4.1.3. By Product
    • 9.2.4.2. UAE
    • 9.2.4.2.1. By Animal
    • 9.2.4.2.2. By Route of Administration
    • 9.2.4.2.3. By Product
    • 9.2.4.3. Qatar
    • 9.2.4.3.1. By Animal
    • 9.2.4.3.2. By Route of Administration
    • 9.2.4.3.3. By Product
    • 9.2.4.4. Kuwait
    • 9.2.4.4.1. By Animal
    • 9.2.4.4.2. By Route of Administration
    • 9.2.4.4.3. By Product
    • 9.2.4.5. South Africa
    • 9.2.4.5.1. By Animal
    • 9.2.4.5.2. By Route of Administration
    • 9.2.4.5.3. By Product
    • 9.2.4.6. Nigeria
    • 9.2.4.6.1. By Animal
    • 9.2.4.6.2. By Route of Administration
    • 9.2.4.6.3. By Product
    • 9.2.4.7. Algeria
    • 9.2.4.7.1. By Animal
    • 9.2.4.7.2. By Route of Administration
    • 9.2.4.7.3. By Product
    • 9.2.4.8. Rest of MEA
    • 9.2.4.8.1. By Animal
    • 9.2.4.8.2. By Route of Administration
    • 9.2.4.8.3. By Product

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Companion Animal Pharmaceuticals Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Companion Animal Pharmaceuticals Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Zoetis Inc.
• 12.2. Merck Animal Health
• 12.3. Boehringer Ingelheim International GmbH
• 12.4. Elanco Animal Health Incorporated
• 12.5. Bayer AG
• 12.6. Virbac
• 12.7. Dechra Pharmaceuticals PLC
• 12.8. Vetoquinol SA
• 12.9. Ceva Sante Animale
• 12.10. Kindred Biosciences, Inc.
• 12.11. Norbrook
• 12.12. IDEXX Laboratories, Inc.
• 12.13. Animalcare Group plc
• 12.14. Neogen Corporation
• 12.15. Heska Corporation
• 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations